On 14 November 2026, China published the 2026 edition of its national drug reimbursement catalogue. Among the 107 medicines newly listed is iza-bren, an EGFR×HER3 bispecific antibody-drug conjugate developed by Baili Tianheng, and the indication it was listed for is relapsed or metastatic nasopharyngeal cancer (NPC) — a disease concentrated in South China, Southeast Asia and parts of the Middle East and North Africa, which is precisely where China's inbound cancer patients come from. The new catalogue takes effect on 1 January 2027 (China News Service). For an international patient deciding whether nasopharyngeal cancer treatment in China is worth pursuing, the news does not simply mean "cheaper drug". It changes the order in which approval, stocking and payment happen — and that order is what determines whether a plan is realistic.
What changed, and on which dates
The 2026 catalogue was announced at the 2026 Innovative Drug High-Quality Development conference, alongside a first batch of 12 medicines added to a separate commercial-insurance innovative drug catalogue (Xinhua). CAR-T products entered the basic catalogue for the first time in the same round of adjustment. For iza-bren, three dates matter:
- June 2026 — approved in China for previously treated (later-line) nasopharyngeal cancer.
- July 2026 — a second China approval for recurrent or metastatic oesophageal squamous cell carcinoma in adults who failed a PD-1/PD-L1 inhibitor plus platinum-containing chemotherapy.
- 1 January 2027 — reimbursement becomes effective, for the NPC indication only, defined in the catalogue as relapsed/metastatic NPC after failure of at least two lines of systemic chemotherapy in which a PD-1/PD-L1 inhibitor had been used.
The company describes it as the world's first approved EGFR×HER3 bispecific ADC, and it is currently marketed only in China. Its clinical footprint is broader than its market: more than 45 studies are running in China and the United States, 20 of them phase III, and four results were selected for the October 2026 ESMO congress, with two phase III studies in breast and lung cancer presented as late-breaker abstracts. Those later read-outs are not the reimbursed indication, and a patient should not build a plan on them.
Why the geography is the point
An approval that exists in one country is only an option if the eligible patient can physically reach it. For a patient in Kuala Lumpur, Jakarta, Bangkok, Karachi or Dubai whose tumour has progressed through two chemotherapy lines plus immunotherapy, the domestic choices are usually re-challenge, a trial if one is recruiting, or best supportive care. China is the only market where this particular drug is on the shelf, which converts a "drug approved somewhere" story into a practical access question: can I get the appointment, can I pay for it, and how long must I stay. That is a logistics and payment problem more than a scientific one, and it is the reason our cancer treatment in China service starts from records review rather than from drug names.
Nothing on this page is medical advice. A treatment plan for nasopharyngeal cancer must be assessed in person by a licensed physician who has reviewed the patient's pathology, imaging and complete prior treatment history.
The timeline a foreign patient should plan around
Approval, reimbursement and actual availability are separate events, and the gaps between them are where trips go wrong.
| Milestone | Status as of November 2026 | What it means for planning |
|---|---|---|
| Regulatory approval (China) | NPC later-line indication from June 2026; oesophageal squamous cell carcinoma from July 2026 | Prescription is legal within the approved wording only |
| Reimbursement effective | 2026 catalogue published 14 Nov 2026, in force 1 Jan 2027 | Applies inside China's basic medical insurance, not to visiting self-payers |
| Hospital stocking | Varies by city and by institution; not announced as a single national date | Must be confirmed with the treating department in writing |
| Records and pathology re-review | Required before treatment can be scheduled | Typically the longest patient-side wait |
| Medical visa and stay length | Arranged per planned treatment schedule | Match the visit category and duration to the cycle plan |
Two cautions sit inside that table. A drug being on a national list does not mean every hospital stocks it, so the appointment and a stocking confirmation are the same question, not two. And a reimbursement date is not a price a foreign patient receives: it is a date from which Chinese insured patients can be reimbursed for the listed indication.
Who pays: three channels, three different bills
China's payment structure now has two catalogues plus one non-catalogue route, and they behave very differently for someone arriving on a passport.
Basic medical insurance (the catalogue this news cycle changed). Reimbursement is tied to participation in China's social medical insurance. A patient visiting from abroad normally pays as a self-pay patient and is quoted the hospital's current price. Any price in this article's comments section, in an agent's email or in a foreign press release should be treated as provisional; request a dated written quotation from the receiving hospital, because self-pay drug and administration costs are set at institution level and move with procurement policy.
The commercial-insurance innovative drug catalogue. This is the newer "second payment channel", and the rollout numbers explain why it matters for availability rather than for reimbursement: by the end of October 2026, the 18 medicines on its first version were stocked at 1,710 designated hospitals and pharmacies, roughly 140% more than before they were listed, with nearly 30,000 recorded uses and around RMB 600 million in sales (Xinhua). Of the 107 additions to the basic catalogue this round, 51 are reported as Class 1 innovative drugs, and the channel between the two catalogues is being widened. For a self-paying patient the practical effect is mundane but valuable: the list of institutions that actually hold advanced therapies is growing, so a plan no longer depends on one or two centres.
Clinical development. Trials and investigator-initiated studies sit outside both catalogues and are discussed below.
| Route | What you pay | Typical timeline | Best fit |
|---|---|---|---|
| Marketed drug, self-pay | Drug, infusion and in-hospital care at the institution's current quote | Once appointment, stocking and pathology review are confirmed | Progression through the approved lines of therapy |
| Reimbursement in China's basic insurance | Patient cost-share under the listed indication | Effective 1 Jan 2027, for catalogue participants | Patients who hold Chinese medical insurance |
| Trial / investigator-initiated study | Investigational product usually not charged; visits, lodging and standard care still cost | Set by protocol, including mandatory follow-up | Patients who do not meet the approved indication, or who want earlier-generation access |
The parallel route: why some studies open in China first
The same news cycle also shows how China's development sequence can run ahead of Western timelines. On 11 November 2026, IasoBio announced that its IND for IASO208 — a CD20-targeted in vivo CAR-T built on its InTelliCAR platform — was approved by China's NMPA, after the same application received US FDA clearance in September 2026; the company describes it as the first lentiviral-vector in vivo CAR-T from China to obtain an FDA IND. The intended indication is relapsed/refractory large B-cell non-Hodgkin lymphoma, and the plan is to run a phase Ib study in the United States directly on data from Chinese investigator-initiated trials, without repeating early dose escalation (IasoBio announcement).
Read as background rather than as an option list, that tells you two things. First, Chinese IIT data can be the evidence base that later supports studies elsewhere, which is why a recruiting study in China may be open a year or more before the equivalent site in Europe or North America. Second, the access model is different from buying a medicine: a trial spares you the drug price but binds you to protocol visits and follow-up, so visa duration, lodging and a local coordinating team become part of the cost. The shift from patient-by-patient, weeks-long manufacturing to an injectable in vivo design also changes how short or long a stay is realistic — a point worth understanding before comparing CAR-T therapy in China with any other option, as does the published cost picture for CAR-T.
How to check whether a specific drug is really reachable
Before committing to travel, work through these five checks in order:
- Approval status and the exact indication wording. Not "approved in China", but approved for which line of therapy, which histology and which prior treatments. This is where eligibility is usually decided.
- Stocking at the treating department. Ask the hospital whether it currently holds the drug and on what schedule it is prescribed, before booking anything else.
- A dated, written self-pay quotation covering drug, infusion, tests, imaging review, admission if any, and repeat cycles.
- The clinical plan around the drug. Which line it is, what happens on progression, and whether a study is a better fit — see our guide to choosing a hospital for cancer treatment in China for the institutional side of that question.
- Stay length and entry documents. Cycle schedules and mandatory follow-up determine visa length; the China medical visa guide covers the paperwork, and hospital appointments in Shanghai covers how the first visit is actually scheduled.
If the tumour type is not NPC or oesophageal squamous cell carcinoma, the same framework applies to any innovative drug with a China-first approval — which is why we treat the 2027 reimbursement round as a case study in sequencing rather than as a single headline.
Next step
Send us the pathology report, the chemotherapy and immunotherapy history with dates, and the most recent imaging, and we will tell you plainly whether China is a realistic option and what the current quote and schedule look like. Submit your case for evaluation at /case-evaluation, or start a conversation at /inquiry. OriEast provides medical translation, hospital appointment arrangement and day-to-day care coordination for international patients, and you can also reach the team directly at /contact.